Melamed D, Friedman A
Department of Animal Sciences, Hebrew University of Jerusalem, Rehovot, Israel.
Eur J Immunol. 1993 Apr;23(4):935-42. doi: 10.1002/eji.1830230426.
The present study investigated bystander suppression, specific suppression and anergy as mechanisms for oral tolerance. Oral tolerance was induced in mice by a single gastric intubation of 20 mg ovalbumin (OVA) and was evaluated in vitro by the absence of T lymphocyte proliferative responses to OVA after priming by OVA-complete Freund's adjuvant (CFA). T lymphocyte unresponsiveness was antigen specific, systemic and was not affected by the vehicle used for immunization. T lymphocytes derived from tolerant popliteal lymph nodes (PLN) responded to an acetone precipitate (AP) of mycobacteria present in CFA; this response was not suppressed by co-culture with OVA, thereby arguing against a mechanism of bystander suppression in our system. Responses of PLN T lymphocytes derived from OVA-CFA primed, non-tolerant mice, or those of an OVA-specific T lymphocyte line, were not suppressed by PLN or spleen cells derived from OVA tolerant mice. These results excluded the possibility that oral tolerance was induced and maintained by a mechanism of specific suppression. At the cellular level, we found that OVA-tolerant T lymphocytes did not produce interleukin-2 (IL-2) nor express IL-2 receptor in response to OVA stimulation in vitro; both observations are indicative of a state of anergy. Incubation of OVA-tolerant PLN T lymphocytes together with murine recombinant IL-2 for 5 days, released anergic T lymphocytes and a concomitant OVA-specific proliferative response of CD4+ T cells was detected. Taken together, our experimental system excludes the involvement of bystander or specific suppression in the induction of oral tolerance to OVA, and provides direct evidence to show that oral tolerance results from specific T lymphocyte anergy.
本研究调查了旁观者抑制、特异性抑制和无反应性作为口服耐受的机制。通过单次胃内灌注20mg卵清蛋白(OVA)在小鼠中诱导口服耐受,并通过OVA完全弗氏佐剂(CFA)致敏后对OVA的T淋巴细胞增殖反应缺失在体外进行评估。T淋巴细胞无反应性是抗原特异性的、全身性的,且不受用于免疫的载体影响。来自耐受腘窝淋巴结(PLN)的T淋巴细胞对CFA中存在的分枝杆菌丙酮沉淀物(AP)有反应;该反应不会因与OVA共培养而受到抑制,因此反对我们系统中旁观者抑制的机制。来自OVA-CFA致敏的非耐受小鼠的PLN T淋巴细胞或OVA特异性T淋巴细胞系的反应,不会被来自OVA耐受小鼠的PLN或脾细胞所抑制。这些结果排除了口服耐受通过特异性抑制机制诱导和维持的可能性。在细胞水平上,我们发现OVA耐受的T淋巴细胞在体外对OVA刺激不产生白细胞介素-2(IL-2),也不表达IL-2受体;这两个观察结果均表明处于无反应状态。将OVA耐受的PLN T淋巴细胞与小鼠重组IL-2一起孵育5天,释放出无反应性T淋巴细胞,并检测到CD4+ T细胞随之出现的OVA特异性增殖反应。综上所述,我们的实验系统排除了旁观者或特异性抑制在对OVA口服耐受诱导中的参与,并提供了直接证据表明口服耐受是由特异性T淋巴细胞无反应性导致的。